@the_real_mchenz @jtrebach While improved pharmacokinetics are appreciated, it's not entirely clear that new formulations result in better clinical outcomes and warrant a *century* of patent protection. For example, compare NPH insulin (1947 patent) to gl
RT @CochraneUK: (Ultra‐)long‐acting #insulin analogues compared with NPH insulin (human isophane insulin) for adults with #type2diabetes me…
(Ultra‐)long‐acting #insulin analogues compared with NPH insulin (human isophane insulin) for adults with #type2diabetes mellitus https://t.co/z9iiB6h2VN Updated @CochraneAbdoEnd review includes 24 RCTs. "The different insulins reduced HbA1c by about the s
RT @Links_Medicus: Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in…
RT @Links_Medicus: Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in…
Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in reduced risk of hypoglycemia but no difference in HbA1c – via @CochraneLibrary https://t.co/5fU9FOwNJU Summary: https://t.co/DS0WI9q1
RT @CochraneLibrary: (Ultra‐)long‐acting #insulin analogues compared with NPH insulin (human isophane insulin) for adults with #type2diabet…
(Ultra‐)long‐acting #insulin analogues compared with NPH insulin (human isophane insulin) for adults with #type2diabetes mellitus https://t.co/BC1gfNi5BK Updated @CochraneAbdoEnd review includes 24 RCTs. "The different insulins reduced HbA1c by about the s